http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 17:17:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+GRAHAM+PETER+J/26729491.html si-local-file:///var/storage/secattach/20260702/26729491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+GRAHAM+PETER+J/26729491.html Thu, 02 Jul 2026 17:17:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+GRAHAM+PETER+J/26729491.html si-local-file:///var/storage/secattach/20260702/26729491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+GRAHAM+PETER+J/26729491.html Thu, 02 Jul 2026 17:17:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Zaki+Mohamed/26729502.html si-local-file:///var/storage/secattach/20260702/26729502.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Zaki+Mohamed/26729502.html Thu, 02 Jul 2026 17:17:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Zaki+Mohamed/26729502.html si-local-file:///var/storage/secattach/20260702/26729502.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Zaki+Mohamed/26729502.html Thu, 02 Jul 2026 17:17:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Carmona+Jose/26729483.html si-local-file:///var/storage/secattach/20260702/26729483.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Carmona+Jose/26729483.html Thu, 02 Jul 2026 17:16:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Carmona+Jose/26729483.html si-local-file:///var/storage/secattach/20260702/26729483.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+Carmona+Jose/26729483.html Thu, 02 Jul 2026 17:16:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+MALLIK+AMEET/26729475.html si-local-file:///var/storage/secattach/20260702/26729475.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+MALLIK+AMEET/26729475.html Thu, 02 Jul 2026 17:15:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+MALLIK+AMEET/26729475.html si-local-file:///var/storage/secattach/20260702/26729475.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30++Filed+by%3A+MALLIK+AMEET/26729475.html Thu, 02 Jul 2026 17:15:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30/26729365.html si-local-file:///var/storage/secattach/20260702/26729365.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30/26729365.html Thu, 02 Jul 2026 17:07:00 -0400 ADCT O.11232467 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30/26729365.html si-local-file:///var/storage/secattach/20260702/26729365.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ADC+Therapeutics+SA+++++++For%3A+Jun+30/26729365.html Thu, 02 Jul 2026 17:07:00 -0400 ADCT O.11232467 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.launne" idsrc="xmltag.org" >LAUSANNE</location>, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on <chron>July 1, 2026</chron> ("Grant").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html Wed, 01 Jul 2026 16:05:00 -0400 ADCT O.11232467 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.launne" idsrc="xmltag.org" >LAUSANNE</location>, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on <chron>July 1, 2026</chron> ("Grant").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html Wed, 01 Jul 2026 16:05:00 -0400 ADCT O.11232467 http://www.streetinsider.com/PRNewswire/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.launne" idsrc="xmltag.org" >LAUSANNE</location>, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on <chron>July 1, 2026</chron> ("Grant").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html Wed, 01 Jul 2026 16:05:00 -0400 ADCT O.11232467 http://www.streetinsider.com/PRNewswire/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.launne" idsrc="xmltag.org" >LAUSANNE</location>, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on <chron>July 1, 2026</chron> ("Grant").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/ADC+Therapeutics+Announces+New+Employee+Inducement+Grant/26720578.html Wed, 01 Jul 2026 16:05:00 -0400 ADCT O.11232467 http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html <p>ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).</p> <p>The trial enrolled 100 r/r DLBCL patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab across 30 sites, with 70% of patients in the United States and 30% in the European Union. The enrolled patient population included 46% relapsed and 54% primary refractory patients, with a median age of 66 years.</p> <p>Primary endpoints of the study include safety and tolerability. http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html Tue, 30 Jun 2026 07:15:15 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html <p>ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).</p> <p>The trial enrolled 100 r/r DLBCL patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab across 30 sites, with 70% of patients in the United States and 30% in the European Union. The enrolled patient population included 46% relapsed and 54% primary refractory patients, with a median age of 66 years.</p> <p>Primary endpoints of the study include safety and tolerability. http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html Tue, 30 Jun 2026 07:15:15 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html <p>ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).</p> <p>The trial enrolled 100 r/r DLBCL patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab across 30 sites, with 70% of patients in the United States and 30% in the European Union. The enrolled patient population included 46% relapsed and 54% primary refractory patients, with a median age of 66 years.</p> <p>Primary endpoints of the study include safety and tolerability. http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html Tue, 30 Jun 2026 07:15:15 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html <p>ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).</p> <p>The trial enrolled 100 r/r DLBCL patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab across 30 sites, with 70% of patients in the United States and 30% in the European Union. The enrolled patient population included 46% relapsed and 54% primary refractory patients, with a median age of 66 years.</p> <p>Primary endpoints of the study include safety and tolerability. http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html Tue, 30 Jun 2026 07:15:15 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html <p>ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).</p> <p>The trial enrolled 100 r/r DLBCL patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab across 30 sites, with 70% of patients in the United States and 30% in the European Union. The enrolled patient population included 46% relapsed and 54% primary refractory patients, with a median age of 66 years.</p> <p>Primary endpoints of the study include safety and tolerability. http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html Tue, 30 Jun 2026 07:15:15 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html <p>ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).</p> <p>The trial enrolled 100 r/r DLBCL patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab across 30 sites, with 70% of patients in the United States and 30% in the European Union. The enrolled patient population included 46% relapsed and 54% primary refractory patients, with a median age of 66 years.</p> <p>Primary endpoints of the study include safety and tolerability. http://www.streetinsider.com/FDA/ADC+Therapeutics+completes+enrollment+in+LOTIS-7+lymphoma+trial/26709499.html Tue, 30 Jun 2026 07:15:15 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html <div class="xn-content"> <p class="prntac"><i>100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab</i></p><p class="prntac"><i>Full data expected in fourth quarter of 2026</i></p><p><span class="legendSpanClass">LAUSANNE, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>June 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ADCT" idsrc="xmltag.org" >ADC Therapeutics SA</span> (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the <money>LOTIS-7</money> Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html Tue, 30 Jun 2026 07:15:00 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html <div class="xn-content"> <p class="prntac"><i>100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab</i></p><p class="prntac"><i>Full data expected in fourth quarter of 2026</i></p><p><span class="legendSpanClass">LAUSANNE, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>June 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ADCT" idsrc="xmltag.org" >ADC Therapeutics SA</span> (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the <money>LOTIS-7</money> Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html Tue, 30 Jun 2026 07:15:00 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html <div class="xn-content"> <p class="prntac"><i>100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab</i></p><p class="prntac"><i>Full data expected in fourth quarter of 2026</i></p><p><span class="legendSpanClass">LAUSANNE, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>June 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ADCT" idsrc="xmltag.org" >ADC Therapeutics SA</span> (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the <money>LOTIS-7</money> Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html Tue, 30 Jun 2026 07:15:00 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html <div class="xn-content"> <p class="prntac"><i>100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab</i></p><p class="prntac"><i>Full data expected in fourth quarter of 2026</i></p><p><span class="legendSpanClass">LAUSANNE, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>June 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ADCT" idsrc="xmltag.org" >ADC Therapeutics SA</span> (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the <money>LOTIS-7</money> Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html Tue, 30 Jun 2026 07:15:00 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html <div class="xn-content"> <p class="prntac"><i>100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab</i></p><p class="prntac"><i>Full data expected in fourth quarter of 2026</i></p><p><span class="legendSpanClass">LAUSANNE, <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></span>, <span class="legendSpanClass"><chron>June 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ADCT" idsrc="xmltag.org" >ADC Therapeutics SA</span> (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the <money>LOTIS-7</money> Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma http://www.streetinsider.com/Press+Releases/ADC+Therapeutics+Announces+Completion+of+Enrollment+in+LOTIS-7+Phase+1b+ZYNLONTA%C2%AE+Combination+Trial/26709498.html Tue, 30 Jun 2026 07:15:00 -0400 A.06822034 A.31066700 ADCT O.11232467 O.20026344 O.22422661